Alixorexton

Alixorexton
Clinical data
Other names	ALKS-2680; ALKS2680
Routes of; administration	Oral
Drug class	Orexin OX2 receptor agonist; Wakefulness-promoting agent
Identifiers
	IUPAC name N-[(15S,16R)-10-oxo-8,18-dioxa-11-azatetracyclo[17.2.2.02,7.011,16]tricosa-2,4,6-trien-15-yl]methanesulfonamide;
CAS Number	2648347-56-0;
PubChem CID	156417714;
IUPHAR/BPS	13879;
UNII	3BRW4ARU66;
KEGG	D13336;
Chemical and physical data
Formula	C21H30N2O5S
Molar mass	422.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N2CCC[C@@H]([C@@H]2CO[C@@H]3CC[C@@H](CC3)C4=C(OC1)C=CC=C4)NS(=O)(C)=O;
	InChI InChI=1S/C21H30N2O5S/c1-29(25,26)22-18-6-4-12-23-19(18)13-27-16-10-8-15(9-11-16)17-5-2-3-7-20(17)28-14-21(23)24/h2-3,5,7,15-16,18-19,22H,4,6,8-14H2,1H3/t15?,16?,18-,19-/m0/s1; Key:IHNJMACFBQEKRJ-VHZYLWGESA-N;

Alixorexton (INNTooltip International Nonproprietary Name; developmental code name ALKS-2680) is an orexin receptor agonist which is under development for the treatment of sleep disorders, including narcolepsy and idiopathic hypersomnia. Alixorexton is being developed by Alkermes As of July 2025, it is in phase 2 clinical trials with planned advancement to a phase 3 study for the treatment of narcolepsy type 1.

References

↑ "Alixorexton - Alkermes". AdisInsight. Springer Nature Switzerland AG. Retrieved 2025-07-30.
↑ Morse AM (May 2025). "Enhancing the Management of Hypersomnia: Examining the Role of the Orexin System". Seminars in Neurology. 45 (3): 410–419. doi:10.1055/a-2589-3825. PMID 40239951.
↑ Prakash BA, Shah I, Ni G, Vasudevan S, Jagannath A, Foster RG (May 2025). "Dreaming of Better Treatments: Advances in Drug Development for Sleep Medicine and Chronotherapy". Journal of Sleep Research. 34 (5) e70087. doi:10.1111/jsr.70087. PMID 40346938.
1 2 Chen E (2025-07-21). "Alkermes drug helped narcolepsy patients stay awake in Phase 2 trial". STAT. Retrieved 2025-07-30.

This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information.

[1] "Alixorexton - Alkermes". AdisInsight. Springer Nature Switzerland AG. Retrieved 2025-07-30.

[Morse_2025-2] Morse AM (May 2025). "Enhancing the Management of Hypersomnia: Examining the Role of the Orexin System". Seminars in Neurology. 45 (3): 410–419. doi:10.1055/a-2589-3825. PMID 40239951.

[Prakash_2025-3] Prakash BA, Shah I, Ni G, Vasudevan S, Jagannath A, Foster RG (May 2025). "Dreaming of Better Treatments: Advances in Drug Development for Sleep Medicine and Chronotherapy". Journal of Sleep Research. 34 (5) e70087. doi:10.1111/jsr.70087. PMID 40346938.

[Chen_2025-4] 1 2 Chen E (2025-07-21). "Alkermes drug helped narcolepsy patients stay awake in Phase 2 trial". STAT. Retrieved 2025-07-30.

v t e Wakefulness-promoting agents
Catecholaminergic agents	Dopamine reuptake inhibitors (DRIs): Adrafinil^‡ Armodafinil Esmodafinil Mesocarb^‡ Modafinil Phenylpiracetam (fonturacetam) Norepinephrine reuptake inhibitors (NRIs): Atomoxetine Desipramine Reboxetine Viloxazine Norepinephrine–dopamine reuptake inhibitors (NDRIs): Amineptine^‡ Bupropion Dexmethylphenidate Methylphenidate Nomifensine^‡ Serdexmethylphenidate Solriamfetol Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs): Mazindol Norepinephrine releasing agents (NRAs): Ephedrine Pseudoephedrine Selegiline (via metabolites) Norepinephrine–dopamine releasing agents (NDRAs): Amphetamine Dextroamphetamine Levoamphetamine^‡ Lisdexamfetamine Methamphetamine Mixed amphetamine salts Pemoline^‡
Orexin receptor agonists	Alixorexton^§ Balumorexton^§ Cleminorexton^§ Danavorexton^§ Firazorexton^§ Ledasorexton^§ Oveporexton
Histamine H₃ receptor antagonists	Pitolisant Samelisant^§
Adenosine receptor antagonists	Caffeine Istradefylline Paraxanthine
Others	GABA_A receptor antagonists and negative allosteric modulators (e.g., clarithromycin, flumazenil, pentylenetetrazol (pentetrazol)) GABA_B receptor agonists (e.g., sodium oxybate/γ-hydroxybutyrate (GHB)) (via improved nightly sleep) Nicotinic acetylcholine receptor agonists (e.g., nicotine)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III
See also: Stimulants List of investigational narcolepsy and hypersomnia drugs

Clinical data

Other names	ALKS-2680; ALKS2680
Routes of administration	Oral
Drug class	Orexin OX₂ receptor agonist; Wakefulness-promoting agent
Identifiers
IUPAC name N-[(15S,16R)-10-oxo-8,18-dioxa-11-azatetracyclo[17.2.2.0^2,7.0^11,16]tricosa-2,4,6-trien-15-yl]methanesulfonamide
CAS Number	2648347-56-0
PubChem CID	156417714
IUPHAR/BPS	13879
UNII	3BRW4ARU66
KEGG	D13336
Chemical and physical data
Formula	C₂₁H₃₀N₂O₅S
Molar mass	422.54 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C1N2CCC[C@@H]([C@@H]2CO[C@@H]3CC[C@@H](CC3)C4=C(OC1)C=CC=C4)NS(=O)(C)=O
InChI InChI=1S/C21H30N2O5S/c1-29(25,26)22-18-6-4-12-23-19(18)13-27-16-10-8-15(9-11-16)17-5-2-3-7-20(17)28-14-21(23)24/h2-3,5,7,15-16,18-19,22H,4,6,8-14H2,1H3/t15?,16?,18-,19-/m0/s1 Key:IHNJMACFBQEKRJ-VHZYLWGESA-N

Alixorexton

See also

References